Key Takeaways
- The US President has signed an executive order to reschedule marijuana from a Schedule I to a Schedule III controlled substance, allowing for easier research and certain regulations.
- The move acknowledges the medical benefits of cannabis and reduces its classification as a highly dangerous and addictive substance.
- The change does not legalize marijuana nationwide, but rather aligns it with certain prescription pain medications and keeps recreational use illegal at the federal level.
- The order directs the Department of Health and Human Services to develop research methods to study the long-term health effects of medical marijuana and hemp-derived cannabinoid products.
- The move has been welcomed by advocates, but they argue that it falls short of the changes necessary to bring federal marijuana policy into the 21st century.
Introduction to the Executive Order
The President of the United States has signed an executive order that reschedules marijuana from a Schedule I to a Schedule III controlled substance. This change is expected to have a significant impact on the way cannabis is treated at the federal level, making it easier to conduct research and reducing certain regulations. The President announced the move from the Oval Office, stating that it would make it far easier to conduct marijuana-related medical research and allow for the study of benefits, potential dangers, and future treatments.
The Impact of the Executive Order
The executive order allows for a pilot program that reimburses Medicare patients for products containing CBD, a widely used cannabis-derived compound that does not produce a high. The move also shifts marijuana from Schedule I, a category that includes heroin, to Schedule III, which includes ketamine. This change aligns marijuana with certain prescription pain medications, while keeping recreational use illegal at the federal level. The change will still need to go through the Drug Enforcement Administration’s formal rule-making process. The reclassification is expected to make scientific research easier, as well as ease burdens on legal cannabis businesses by reducing strict federal tax penalties and improving access to banking services.
The Reaction to the Executive Order
The executive order has been welcomed by advocates of cannabis reform, who argue that it is a step in the right direction. Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws, stated that the order "validates the experiences of tens of millions of Americans, as well as those of tens of thousands of physicians, who have long recognized that cannabis possesses legitimate medical utility". However, Armentano also noted that the move falls short of the changes necessary to bring federal marijuana policy into the 21st century, referencing the fact that 24 US states have already legalized the use and sale of the substance.
The Future of Cannabis Research
The executive order directs the Department of Health and Human Services to develop "research methods and models utilizing real-world evidence" to study the long-term health effects of medical marijuana and hemp-derived cannabinoid products. This move is expected to lead to a greater understanding of the benefits and risks of cannabis, and could potentially lead to the development of new treatments and products. The order also states that the White House will work with Congress to expand access to appropriate full-spectrum CBD products, while restricting products that pose serious health risks. According to the order, one in five US adults and nearly 15% of seniors reported using CBD in the past year.
The Current State of Cannabis Law
The current state of cannabis law in the US is complex and often contradictory. While 24 states have legalized the use and sale of marijuana, it remains illegal at the federal level. This has created a number of challenges for businesses and individuals who wish to use or sell cannabis products. The executive order is seen as a step towards resolving these contradictions, but it is unclear how it will be implemented and what impact it will have on the ground. Pew research suggests that 57% of Americans think cannabis should be legal for medical and recreational purposes, while 32% think it should be legal for medical use only.
Conclusion
The executive order signed by the President is a significant step towards reforming the US’s cannabis laws. While it does not go as far as some advocates would like, it acknowledges the medical benefits of cannabis and reduces its classification as a highly dangerous and addictive substance. The move is expected to lead to a greater understanding of the benefits and risks of cannabis, and could potentially lead to the development of new treatments and products. However, it remains to be seen how the order will be implemented and what impact it will have on the ground. As the US continues to grapple with the complexities of cannabis law, it is clear that this is an issue that will continue to evolve and change in the years to come.